Amgen Palifermin BLA Is First For Mucositis; Priority Review Expected
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amgen’s recent BLA submission for palifermin could make the agent the first treatment approved to reduce the duration and severity of oral mucositis.